Haemonetics price target raised to $90 from $71 at Barrington. Barrington analyst Michael Petusky raised his price target for Haemonetics to $90 citing the company’s “solid” Q4 results and “strong” fiscal 2019 guidance. The analyst has increasing confidence that Haemonetics is executing against its key strategic goals. He keeps an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.